Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions

Thrombosis and Haemostasis

Volumn 109, Issue 1, 2013, Pages 127-136

  Mani, Helen ^a   Hesse, Christian ^a   Stratmann, Gertrud ^a   Lindhoff Last, Edelgard ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Clotting factor activity; D dimer; Lupus anticoagulants; Protein C; Protein S; Rivaroxaban; Von Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 6; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CARDIOLIPIN ANTIBODY; D DIMER; HEPARIN PLATELET FACTOR 4 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN; RIVAROXABAN; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD CLOTTING TEST; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOSTASIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; PRIORITY JOURNAL; THROMBOCYTE POOR PLASMA; THROMBOPHILIA; TURBIDIMETRY;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMOGENIC COMPOUNDS; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XA; FALSE POSITIVE REACTIONS; HUMANS; MORPHOLINES; NEPHELOMETRY AND TURBIDIMETRY; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TABLETS; TANDEM MASS SPECTROMETRY; THIOPHENES; THROMBOPHILIA; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872251979     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-04-0228     Document Type: Article

References (18)

1. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
2. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47: 203-216.
3. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-521.
4. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 31; 103: 815-825.
5. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9: 133-139.
6. Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-1271.
7. Mani H, Hesse C, Stratmann G, et al. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 2011; 106: 156-164.
8. Asmis LM, Alberio L, Angelillo-Scherrer A, et al. Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories. Thromb Res 2012; 129: 492-498.
9. Gerotziafas GT, Baccouche H, Sassi M, et al. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thromb Res 2012; 129: 101-103.
10. Tichelaar V, de Jong H, Nijland H, et al. Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays. Thromb Haemost 2011; 106: 990-992.
11. Merriman E, Kaplan Z, Butler J, et al. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost 2011; 105: 385-386.
12. Rohde G. Determination of rivaroxaban-a novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872: 43-50.
13. Pengo V, Tripodi A, Reber G, et al. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737-1740.
14. Lindhoff-Last E, Humpich M, Schmitt J, et al. MIXCON-LA: a precise, sensitive and specific aPTT-based assay for detection of lupus anticoagulant. Clin Appl Thromb Hemost 2002; 8: 163-167.
15. Os GMA, de Laat B, Kamphuisen PW, et al. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost 2011; 9: 1657-1659.
16. Jacobsen EM, Barna-Cler L, Taylor JM, et al. The lupus ratio test an interlaboratory study on the detection of lupus anticoagulants by an APTT-based, integrated and semi-quantitative test. Thromb Haemost 2000; 83: 704-708.
17. Esmon NL, Safa O, Smirnov MD, et al. Antiphospholipid antibodies and the protein C pathway. J Autoimmun 2000; 15: 221-225.
18. Mueck W, Lensing AW, Agnelli G, et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50: 675-686.